Gene therapy for corneal dystrophies and disease, where are we?

Current Opinion in Ophthalmology

Volumn 23, Issue 4, 2012, Pages 276-279

  Williams, Keryn A ^a   Klebe, Sonja ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

corneal dystrophies; corneal transplantation; nanoparticle gene delivery; neovascularization; scarring and haze; viral vectors

Indexed keywords

BACULOVIRUS VECTOR; CANNABINOID 1 RECEPTOR; CHITOSAN; DECORIN; GOLD NANOPARTICLE; LENTIVIRUS VECTOR; MATRIX METALLOPROTEINASE 14; PARVOVIRUS VECTOR; PROTEIN BCL XL; PROTEIN P16; PROTEIN P21; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F2; UNCLASSIFIED DRUG; VASOINHIBIN 1;

APOPTOSIS; CELL DIVISION; CELL SURVIVAL; CONTROLLED STUDY; CORNEA DISEASE; CORNEA DYSTROPHY; CORNEA ENDOTHELIUM; CORNEA NEOVASCULARIZATION; DEBRIDEMENT; ENDOTHELIUM CELL; GENE OVEREXPRESSION; GENE THERAPY; HUMAN; HUMAN TISSUE; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REVIEW; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; WOUND HEALING;

CORNEAL DISEASES; CORNEAL DYSTROPHIES, HEREDITARY; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; TRANSGENES;

EID: 84862519969     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e3283541eb6     Document Type: Review

References (25)

1. Sharma A, Tovey JCK, Ghosh A, Mohan RR. AAV serotype influences gene transfer in corneal stroma in vivo. Exp Eye Res 2010; 91:440-448.
2. Buss DG, Giuliano E, Sharma A, Mohan RR. Gene delivery in the equine cornea: a novel therapeutic strategy. Vet Ophthalmol 2010; 13:301-306.
3. Mohan RR, Sinha S, Tandon A, et al. Efficacious and safe tissue-selective controlled gene therapy approaches for the cornea. PLoS One 2011; 6:e18771; doi: 10.1371/journal.pone.0018771.
4. Galiacy SD, Fournié P, Massoudi D, et al. Matrix metalloproteinase 14 overexpression reduces corneal scarring. Gene Ther 2011; 18:462-468.
5. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358:2231-2239.
6. Parker DG, Coster DJ, Brereton HM, et al. Lentivirus-mediated gene transfer of interleukin 10 to the ovine and human cornea. Clin Exp Ophthalmol 2010; 38:405-413.
7. De Oliveira LA, Kim C, Barbosa de Sousa L, et al. Gene transfer to primary corneal epithelial cells with an integrating lentiviral vector. Arq Bras Oftalmol 2010; 73:447-453.
8. Saghizadeh M, Kramerov AA, Yu F-SX, et al. Normalization of wound healing and diabetic markers in organ cultured human diabetic corneas by adenoviral delivery of c-Met gene. Invest Ophthalmol Vis Sci 2010; 51:1970-1980.
9. Zhou S-Y, Xie Z-L, Xiao O, et al. Inhibition of mouse alkali burn inducedcorneal neovascularization by recombinant adenovirus encoding human vasohibin-1. Mol Vis 2010; 16:1389-1398.
10. De la Fuente M, Raviña M, Paolicelli P, et al. Chitosan-based nanostructures: A delivery platform for ocular therapeutics. Adv Drug Deliv Rev 2010; 62:100-117
11. Klausner EA, Zhang Z, Chapman RL, et al. Ultrapure chitosan oligomers as carriers for corneal gene transfer. Biomaterials 2010; 31:1814-1820.
12. Sharma A, Tandon A, Tovey JCK, et al. Polyethylenimine-conjugated gold nanoparticles: gene transfer potential and low toxicity in the cornea. Nanomedicine 2011; 7:505-513.
13. Mohan RR, Tovey JCK, Sharma A, Tandon A. Gene therapy in the cornea: 2005-present. Prog Retin Eye Res 2012; 31:43-64.
14. Liao H, Irvine AD, Macewen CJ, et al. Development of allele-specific therapeutic siRNA in Meesmann epithelial corneal dystrophy. PLoS One 2011; 6:e28582. doi: 10.1371/journal.pone.0028582.
15. Pisanti S, Picardi P, Prota L, et al. Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis. Blood 2011; 117:5541-5550
16. MohanRR, ToveyJCK,Sharma A, et al. Targeted decorin gene therapy delivered with adeno-associated virus effectively retards corneal neovascularization in vivo. PLoS One 2011; 10:e26432. doi: 10.1371/journal.pone. 0026432.
17. Mohan RR, Tovey JCK, Gupta R, et al. Decorin biology, expression, function and therapy in the cornea. Curr Mol Med 2011; 11:110-128.
18. Tandon A, Tovey JCK, Sharma A, et al. Role of transforming growth factor beta in corneal function, biology and pathology. Curr Mol Med 2010; 10:565-578.
19. Mohan RR, Gupta R, Mehan MK, et al. Decorin transfection suppresses profibrogenic genes and myofibroblast formation in human corneal fibroblasts. Exp Eye Res 2010; 91:238-245.
20. Mohan RR, Tandon A, Sharma A, et al. Significant inhibition of corneal scarring in vivo with tissue-selective, targeted AAV5 decorin gene therapy. Invest Ophthalmol Vis Sci 2011; 52:4833-4841.
21. McLean WHI, Moore CBT. Keratin disorders: from gene to therapy. Hum Mol Genet 2011; 20:R189-R197.
22. Kampik D, Ali RR, Larkin DFP. Experimental gene transfer to the corneal endothelium. Exp Eye Res 2012; 95:54-59.
23. Fuchsluger TA, Jurkunas U, Kazlauskas A, Dana R. Antiapoptotic gene therapy prolongs survival of corneal endothelial cells during storage.Gene Ther 2011; 18:778-787.
24. Fuchsluger TA, Jurkunas U, Kazlauskas A, Dana R. Corneal endothelial cells are protected from apoptosis by gene therapy. Hum Gene Ther 2011; 22:549-558.
25. Williams KA, Coster DJ. Gene therapy for diseases of the cornea- A review. Clin Exp Ophthalmol 2010; 38:93-103.s